GeneOne Life Science, Inc. (KRX: 011000)

Market Cap	174.43B
Revenue (ttm)	40.80B
Net Income (ttm)	-73.64B
Shares Out	79.83M
EPS (ttm)	-937.97
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	241,319
Open	2,050.00
Previous Close	2,105.00
Day's Range	2,050.00 - 2,130.00
52-Week Range	1,996.00 - 4,735.00
Beta	-2.10
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2024

About GeneOne Life Science

GeneOne Life Science, Inc., a biopharmaceutical company, engages in the research, development, and contract manufacturing of nucleic acid-based biopharmaceuticals. Its small molecule pipeline comprises GLS-1027, which is in Phase I clinical trial for treatment of nephropathy and inflammatory diseases; GLS-1200 that is in Phase II clinical trial to treat Rhinosinusitis; GLS-1027 and GLS-1200, which is Phase II clinical trial for treatment of COVID-19. The company’s nucleic acid vaccines include GLS-3000 mRNA under feasible study and GLS-5310 DNA...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1976
• Employees: 73
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 011000

Financial Performance

In 2023, GeneOne Life Science's revenue was 40.20 billion, a decrease of -17.48% compared to the previous year's 48.72 billion. Losses were -77.77 billion, 103.8% more than in 2022.